Navigation Links
SkinMedica(R) Launches NeoBenz(R) Micro Wash for Acne
Date:1/14/2009

Only Benzoyl Peroxide Wash to Utilize MICROSPONGE(R) Delivery System

CARLSBAD, Calif., Jan. 14 /PRNewswire/ -- SkinMedica, Inc. today announced the launch of NeoBenz Micro Wash, the only prescription benzoyl peroxide wash product formulated with the MICROSPONGE(R) delivery system, for the treatment of mild to moderate acne vulgaris. NeoBenz Micro Wash contains 7% benzoyl peroxide.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090114/LA58962)

NeoBenz Micro Wash follows on the success of NeoBenz Micro Cream and NeoBenz Micro SD which launched in January of 2006 and January of 2007, respectively. Within one year of launch, NeoBenz Micro Cream became the most-prescribed benzoyl peroxide cream or gel by dermatologists.

"NeoBenz Micro Wash is a cosmetically elegant, easy to lather formulation and the only benzoyl peroxide wash medication to utilize the benefits of the MICROSPONGE(R) delivery system. The benzoyl peroxide entrapped microspheres have been shown to remain on the skin post-rinse. This slow release of benzoyl peroxide provides a lower incidence of irritation which may result in improved compliance and better therapeutic results," said Rex Bright, president at SkinMedica.

The clinical benefits of NeoBenz Micro Wash were evaluated in a randomized, investigator-blinded trial comparing the tolerability of NeoBenz Micro Wash with a non-medicated gentle cleansing wash. Forty-six (46) mild to moderate acne patients were assigned to receive once daily treatment with one of the washes for 21 days. Results showed that both groups exhibited excellent local cutaneous tolerability and mean scores measurable at baseline were minimal and improved during the course of the study. There were no statistical differences between the two regimens for erythema, dryness/scaling, burning/stinging or pruritus.

"These data demonstrate a low incidence of irritation for NeoBenz Micro Wash that was on par with the gentle cleansing wash," said investigator Nathan Trookman, MD, Colorado Springs Dermatology Clinic, Colorado Springs, CO.

NeoBenz Micro Wash, NeoBenz Micro Cream and NeoBenz Micro SD are the only prescription products in which the MICROSPONGE(R) delivery system is used in combination with this proven antibacterial acne-fighter. Benzoyl peroxide, entrapped in these porous microspheres, is gradually released onto the skin throughout the day. This gradual, more controlled release is designed to reduce irritation to the skin while the active agent fights existing acne and helps to prevent new pimples from forming.

Acne is a disease for which 5.6 million U.S. patients were diagnosed in the past year. Of these, 2.9 million (52%) were diagnosed by dermatologists. The NeoBenz Micro family of products helps to stop acne and prevent new acne from forming via a multi-pronged approach. The active ingredient, benzoyl peroxide, is released gradually throughout the day to kill the P. acnes bacteria, reduce inflammation, open plugged follicles and slow formation of whiteheads, blackheads and inflamed pimples.

The NeoBenz Micro family of products can also be used in combination therapy (i.e. with topical retinoids or antibiotics) to help increase overall efficacy of treatment, and may also help prevent antibiotic resistance when used with antibiotic treatments.

As with all benzoyl peroxide products, NeoBenz Micro Wash, NeoBenz Micro Cream and NeoBenz Micro SD should not be used in patients who have shown hypersensitivity to benzoyl peroxide or to any of the other ingredients. Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.

MICROSPONGE(R) is a registered trademark of AMCOL International Corporation.

About SkinMedica

SkinMedica, Inc. is focused on developing, acquiring and commercializing products that treat dermatologic conditions and improve the appearance of skin. We market and sell primarily to dermatologists, both prescription pharmaceutical products and physician-dispensed, non-prescription skin care products. SkinMedica's pharmaceutical products include Desonate(R) (desonide) Gel 0.05% for the treatment of mild to moderate atopic dermatitis; VANIQA(R) (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the treatment of unwanted facial hair in women; NeoBenz(R) Micro Cream, NeoBenz(R) Micro SD and NeoBenz(R) Micro Wash, all of which incorporate the patented gradual-release MICROSPONGE(R) delivery system of benzoyl peroxide, for the treatment of acne; and EpiQuin(R) Micro Cream (4% hydroquinone) for the treatment of melasma and postinflammatory hyperpigmentation. The company's full line of aesthetic products -- which began with TNS Recovery Complex(R) as the inspiration for its comprehensive line -- are designed to enhance skin appearance, reduce signs of aging and provide other skin care benefits. SkinMedica is based in Carlsbad, California. For more information, visit: www.skinmedica.com.

Desonate(R), EpiQuin(R) Micro, NeoBenz(R) Micro, SkinMedica(R), TNS Recovery Complex(R) and VANIQA(R) are registered trademarks of SkinMedica, Inc.

    CONTACT:
    Wendy Johnson
    Senior Product Manager, Pharmaceuticals
    760-448-3651
    wjohnson@skinmedica.com


'/>"/>
SOURCE SkinMedica, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. SkinMedica(R) Launches New Informational Web Site
2. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
3. UPMC Health Plan Launches New Personal Health Record
4. HealthInsuranceFinders.com Launches Video Contest for Young Directors
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
7. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
8. Mannatech Launches Phase One of New Sales and Training Tools
9. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
10. Actavis Launches Carvedilol Tablets in the U.S.
11. MedQuist Re-launches New, Improved Web Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: